Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Supreme Court Favors Patent Extension for Takeda's DDS Formulations
May 16, 2011
- Korosho Draws Up Draft Guidance for Risk Management Plans
May 16, 2011
- Kaketsuken, GSK Start PI Trial of New Cell Culture-based Flu Vaccine
May 16, 2011
- Sawai, Takeda Take Actos Patent Dispute to IP High Court
May 16, 2011
- Long-Acting ESA Mircera Approved: Chugai
May 16, 2011
- Korosho Invites Medical Societies to Present Views on 10 Switch OTC Drug Candidates
May 16, 2011
- DSP Licenses Novel Topical Analgesic to Maruho
May 16, 2011
- Glubes Approved for Type 2 Diabetes: Kissei
May 16, 2011
- Sato Pharm. Launches Switch OTC Version of Clotrimazole for Vaginal Candidiasis
May 16, 2011
- Takeda Announces Equity Investment in Fate Therapeutics of US
May 16, 2011
- Once-Daily Mirapex Approved for Parkinson's Disease: NBI
May 16, 2011
- Daiichi Sankyo to Launch AD Treatment MEMARY in June
May 16, 2011
- Pancreatic Digestive Enzyme LipaCreon Approved: Abbott Japan, Eisai
May 16, 2011
- Legal Prescription Receipt Rate Exceeds 65%: JPA
May 16, 2011
- Production to Resume at Takahagi Tech Center in Oct.: Astellas
May 16, 2011
- Tramcet Combination Tab Approved for Relief of Chronic Pain: Janssen
May 16, 2011
- Industry Concerned About Possibility of Consecutive NHI Price Revisions
May 16, 2011
- Takara Bio Aims for Sales of ¥22,700 Mil. in FY2013
May 16, 2011
- Suprane Approved for Inhalation Anesthesia: Baxter
May 16, 2011
- Taiyo Reportedly Seeking Strategic Alliance with Teva
May 16, 2011
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…